How a Tiny “Bug” Can Stop Cancer in its Tracks as a Vaccine
Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat’s intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world’s population, 60 million of which are Americans. Most people have no symptoms, but some experience a flu-like illness. Those with suppressed immune systems, however, can develop a serious infection if they are unable to fend off T. gondii.
An Anti-Cancer Agent in Nature?
A healthy immune system responds vigorously to T. gondii in a manner that parallels how the immune system attacks a tumor.
“We know biologically this parasite has figured out how to stimulate the exact immune responses you want to fight cancer,” said David J. Bzik, PhD, professor of Microbiology and Immunology, Geisel School of Medicine at Dartmouth.
In response to T. gondii, the body produces natural killer cells and cytotoxic T cells. These cell types wage war against cancer cells. Cancer can shut down the body’s defensive mechanisms, but introducing T. gondii into a tumor environment can jump start the immune system.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patientson September 8, 2019 at 9:24 am
CheckMate 817 was started because data are limited on safety and efficacy of immunotherapy in patients with advanced NSCLC with other comorbidities such as brain metastases, kidney and renal ...
- Age affects efficacy of immunotherapy treatment for breast cancer, preclinical study revealson September 8, 2019 at 1:27 am
Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications ...
- IASLC World Conference on Lung Cancer--Press Briefing Summary from Sunday, September 8thon September 8, 2019 at 12:55 am
Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC ... arms in patients with metastatic non-small cell lung cancer and mutations in STK11 or KEAP1 genes compared ...
- Impact of Age on Immunotherapy Treatment for Breast Cancer Revealedon September 7, 2019 at 10:01 pm
Crosstalk between two immune checkpoint blockage therapy was found to be revolutionary especially for its potential to treat patients with triple negative breast cancer (TNBC), stated recent clinical ...
- Improving cancer immunotherapy through nanotechnologyon September 6, 2019 at 3:30 am
The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient’s coordinated and adaptive immune system to fight ...
- Immunotherapy: The Future of Cancer Treatmenton September 5, 2019 at 3:00 am
As an oncologist, nothing makes me happier than to find a therapy that works for one of my patients – something that halts that patient's cancer in its tracks. So I am particularly excited by recent ...
- Immunotherapy for Colon Canceron September 4, 2019 at 5:00 pm
This year it’s estimated that more than 100,000 new cases of colon cancer and an estimated 44,180 new cases of rectal cancer will be diagnosed in the U.S., according to the American Cancer Society.
- Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59Bon August 28, 2019 at 11:37 am
Celgene Corporation (NASDAQ: CELG), which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY), has struck a cell therapy deal with the German biotech Immatics Biotechnologies GmbH ...
- Cancer Immunotherapy Market is Expected to Touch a Value of US$ 145 Billion By 2024on August 28, 2019 at 11:22 am
Aug 28, 2019 (Heraldkeepers) -- New York, August 28, 2019: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the ...
- Phagocytosis checkpoints as new targets for cancer immunotherapyon August 28, 2019 at 7:37 am
Cancer immunotherapies targeting adaptive immune checkpoints have substantially improved patient outcomes across multiple metastatic and treatment-refractory cancer types. However, emerging studies ...
via Bing News